Goodnough Lawrence T
Division of Laboratory Medicine, Washington University School of Medicine, Box 8118, 660 S. Euclid Avenue, St. Louis, MO 63110, USA.
Curr Hematol Rep. 2002 Nov;1(2):119-23.
Erythropoetin therapy has been approved for treatment of medical anemia since 1989. The adoption of this strategy has been rapid in some settings (e.g., renal failure patients) and progressive in others (e.g., cancer patients). Although the risks of blood transfusion have declined substantially, risks associated with (untreated) anemia have undergone new scrutiny. Options such as novel erythropoiesis-stimulating protein bring new alternatives to blood transfusion. Erythropoietin therapy is undergoing renewed scrutiny in the management of anemia, not only because of traditional concerns regarding blood risks but because emerging evidence suggests that improved patient outcomes result from management of anemia.
自1989年以来，促红细胞生成素疗法已被批准用于治疗医学性贫血。在某些情况下（如肾衰竭患者），该策略的采用速度很快，而在其他情况下（如癌症患者）则是逐步推进的。尽管输血风险已大幅降低，但与（未治疗的）贫血相关的风险却受到了新的审视。新型促红细胞生成刺激蛋白等选择为输血带来了新的替代方案。促红细胞生成素疗法在贫血管理中正在接受重新审视，这不仅是因为对血液风险的传统担忧，还因为新出现的证据表明，贫血管理可改善患者预后。
